AU2013204875B2 - Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor - Google Patents

Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor

Info

Publication number
AU2013204875B2
AU2013204875B2 AU2013204875A AU2013204875A AU2013204875B2 AU 2013204875 B2 AU2013204875 B2 AU 2013204875B2 AU 2013204875 A AU2013204875 A AU 2013204875A AU 2013204875 A AU2013204875 A AU 2013204875A AU 2013204875 B2 AU2013204875 B2 AU 2013204875B2
Authority
AU
Australia
Prior art keywords
antibodies
human anti
uses therefor
therefor
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013204875A
Other versions
AU2013204875A1 (en
Inventor
Rafi Ahmed
Francis J. Carr
Gordon J. Freeman
James P. Gregson
Timothy D. Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Emory University
Original Assignee
Dana Farber Cancer Institute Inc
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009296392A external-priority patent/AU2009296392B2/en
Application filed by Dana Farber Cancer Institute Inc, Emory University filed Critical Dana Farber Cancer Institute Inc
Priority to AU2013204875A priority Critical patent/AU2013204875B2/en
Publication of AU2013204875A1 publication Critical patent/AU2013204875A1/en
Application granted granted Critical
Publication of AU2013204875B2 publication Critical patent/AU2013204875B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

AU2013204875A 2008-09-26 2013-04-12 Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor Active AU2013204875B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013204875A AU2013204875B2 (en) 2008-09-26 2013-04-12 Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61/100,534 2008-09-26
AU2009296392A AU2009296392B2 (en) 2008-09-26 2009-09-25 Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
AU2013204875A AU2013204875B2 (en) 2008-09-26 2013-04-12 Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2009296392A Division AU2009296392B2 (en) 2008-09-26 2009-09-25 Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor

Publications (2)

Publication Number Publication Date
AU2013204875A1 AU2013204875A1 (en) 2013-05-09
AU2013204875B2 true AU2013204875B2 (en) 2016-05-12

Family

ID=

Similar Documents

Publication Publication Date Title
IL265397B (en) Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
HRP20180873T1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2010089411A3 (en) Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2310415B8 (en) Antibodies against fcrn and use thereof
KR101882034B1 (en) Methods, devices, and materials for metallization
EP2543507A4 (en) Laminate, method for producing same, and functional element using same
IL212100A0 (en) Cross-species-specific spcaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-irxcd3 or fapalphaxcd3 bispecific single chain antibodies, compositions comprising the same and uses thereof
AP2929A (en) Anti-TRKA antibodies and derivatives thereof
EP2527404A4 (en) Composition for ultraviolet ray-absorbable member, and ultraviolet ray-absorbable member comprising same
EP2558431A4 (en) Narrow psd hydraulic cement-scm blends, and methods for making same
WO2011103490A3 (en) INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
EP2571982A4 (en) Antigen specific tregs and related compositions, methods and systems
EP2540485A4 (en) Composite material repair method, and composite material using same
EP2635051A4 (en) Application shop system and application development method using the application shop system
WO2009154739A3 (en) Smoothened receptor modulators
AU2009213453A8 (en) Anti-ADAM-15 antibodies and utilization of the same
WO2009006359A8 (en) Anti- mcp-1 antibodies, compositions, methods and uses
EP2573731A4 (en) Biological imaging device, and biological imaging method
WO2011088272A9 (en) Selective ampd2 inhibitors and methods for using the same
EP2645255A4 (en) Program generating device, program generating program, and program generating method
AU2013204875B2 (en) Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
EP2576910A4 (en) Method, element and form
AU2007902971A0 (en) Receptors and related methods and products
AU2011903005A0 (en) Sanitary disposal bags, and cream applicator for back
AU2008902059A0 (en) Disposable Hat and Packaging